SYS-CON MEDIA Authors: RealWire News Distribution, Kevin Benedict, Jason Bloomberg, Bob Gourley, Greg Schulz

News Feed Item

HedgePath Pharmaceuticals to Present at 6th Annual Biotech Showcase Conference

Presentation to be held at Monday, January 13, 2014 at 10:00 a.m. Pacific Time at the Parc 55 Wyndam in Union Square, San Francisco

TAMPA, Fla. and SAN DIEGO, Jan. 8, 2014 /PRNewswire/ -- HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that its president and chief executive officer, Mr. Nicholas J. Virca, will present at the 6th Annual Biotech Showcase Conference to be held in San Francisco, California.  The presentation will occur in the Powell Room on Monday, January 13, 2014 at 10:00 a.m. Pacific Time at the Parc 55 Wyndam in Union Square.

Mr. Virca will provide an update on HPPI's ongoing plans to repurpose a patented, specially formulated version of the FDA approved anti-fungal drug itraconazole (known as SUBA™-Itraconazole) as a cancer inhibitor in Phase II clinical trials that HPPI intends to launch during 2014.  He will also discuss the drug's potential for commercialization as an oral oncology therapy based upon previous clinical research undertaken by key investigators in the field for treatment of lung, skin and prostate cancers.

HPPI has signed an exclusive Supply and License Agreement with a wholly owned subsidiary of Mayne Pharma Group Limited, whereby HPPI will pursue clinical development of Mayne Pharma's patented formulation of SUBA-Itraconazole, for treatment of a variety of cancers with a focus on seeking regulatory approvals and marketing in the United States.

"SUBA technology" is designed to improve the bioavailability of orally administered drugs that are poorly soluble.  SUBA-Itraconazole was developed to improve absorption and significantly reduce variability compared to generic itraconazole.  These benefits are designed to provide enhancements to patients and prescribers with reduced intra- and inter-patient variability, enabling the potential for a more predictable clinical response and a reduction in the active drug quantity to deliver the required therapeutic blood levels.

About HedgePath Pharmaceuticals

HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that is seeking to repurpose the FDA approved antifungal pharmaceutical itraconazole as a potential treatment for cancer.  HPPI is the exclusive licensee of a patented formulation of itraconazole, called SUBA-Itraconazole, which clinical studies have shown to have greater bioavailability than generic itraconazole.

The Hedgehog signaling pathway is a major regulator of cellular processes in vertebrates, including cell differentiation, tissue polarity and cell proliferation.  Based on published research, HPPI believes that inhibiting the Hedgehog pathway could delay or possibly prevent the development of certain cancers in humans.  Leveraging research undertaken by key investigators in the field, HPPI plans to explore the effectiveness of SUBA-Itraconazole as a cancer inhibitor and to pursue its potential commercialization.  HPPI has offices in Tampa, Florida and San Diego, California.  For more information, please visit www.hedgepathpharma.com.

Cautionary Note Regarding Forward Looking Statements

This press release, the presentation referred to herein and any statements of representatives and partners of HedgePath Pharmaceuticals, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, the outcome of the Company's collaboration with Mayne and timing for and results of the Company's clinical trials) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

For more information:

Company Contact:
HedgePath Pharmaceuticals, Inc., Nicholas J. Virca, President and CEO, 813-864-2559, [email protected]

Investor Relations Contact:
The Shoreham Group, LLC., Tim Ryan, Managing Director, 212-242-7777, [email protected]

© 2014 HedgePath Pharmaceuticals, Inc.  All rights reserved.

SOURCE HedgePath Pharmaceuticals, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.